Fulgent reported Q4 2025 revenue of USD 83.3 million (+9.0%), with a GAAP net loss attributable to shareholders of USD 23.4 million (USD -0.76 per share). Non-GAAP income was USD 5.2 million (USD 0.16 per share) and adjusted EBITDA was a loss of USD 4.5 million. For FY 2025, revenue was USD 322.7 million (+14.0%), with a GAAP net loss attributable to shareholders of USD 60.5 million (USD -1.97 per share). Non-GAAP income was USD 13.2 million (USD 0.42 per share) and adjusted EBITDA was a loss of USD 9.4 million. Management said the lab services business sustained momentum and cited investments in AI and digital pathology solutions. The company also highlighted progress in its therapeutic development pipeline, with FID-007 advancing through Phase 2 and FID-022 progressing through Phase 1. For FY 2026, Fulgent guided to revenue of approximately USD 350.0 million and a non-GAAP loss of approximately USD -1.45 per share, and expects cash, cash equivalents, restricted cash, and investments in marketable securities of approximately USD 685.0 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260227658778) on February 27, 2026, and is solely responsible for the information contained therein.
Comments